Anchalee Avihingsanon

Summary

Affiliation: The HIV Netherlands Australia Thailand Research Collaboration
Country: Thailand

Publications

  1. ncbi Pharmacokinetics and 48 week efficacy of adjusted dose indinavir/ritonavir in rifampicin-treated HIV/tuberculosis-coinfected patients: a pilot study
    Anchalee Avihingsanon
    HIV Netherlands Australia Thailand Research Collaboration, Thai Red Cross AIDS Research Center, Pathumwan, Bangkok, Thailand
    AIDS Res Hum Retroviruses 28:1170-6. 2012
  2. pmc Assessment of HBV flare in a randomized clinical trial in HIV/HBV coinfected subjects initiating HBV-active antiretroviral therapy in Thailand
    Anchalee Avihingsanon
    The Kirby Institute for Infection and Immunity in Society, University of New South Wales, Sydney, Australia
    AIDS Res Ther 9:6. 2012
  3. doi Efficacy of tenofovir disoproxil fumarate/emtricitabine compared with emtricitabine alone in antiretroviral-naive HIV-HBV coinfection in Thailand
    Anchalee Avihingsanon
    HIV NAT, Thai Red Cross AIDS Research Centre, Bangkok, Thailand
    Antivir Ther 15:917-22. 2010
  4. doi Plasma concentrations of generic lopinavir/ritonavir in HIV type-1-infected individuals
    Jasper van der Lugt
    The HIV Netherlands Australia Thailand Research Collaboration HIV NAT, Thai Red Cross Aids Research Centre TRCARC, Bangkok, Thailand
    Antivir Ther 14:1001-4. 2009
  5. doi Reducing the boosting dose of ritonavir does not affect saquinavir plasma concentrations in HIV-1-infected individuals
    Jasper van der Lugt
    The HIV Netherlands Australia Thailand Research Collaboration, Bangkok, Thailand
    AIDS 23:1176-9. 2009
  6. doi Thai HIV-1-infected women do not require a dose increase of lopinavir/ritonavir during the third trimester of pregnancy
    Reshmie A Ramautarsing
    The HIV Netherlands Australia Thailand Research Collaboration, Bangkok, Thailand
    AIDS 25:1299-303. 2011
  7. doi Pharmacokinetics and 48-week safety and efficacy of generic lopinavir/ritonavir in Thai HIV-infected patients
    Reshmie A Ramautarsing
    The HIV Netherlands Australia Thailand Research Collaboration HIV NAT, Bangkok, Thailand
    Antivir Ther 18:249-52. 2013
  8. pmc Pharmacokinetics of and short-term virologic response to low-dose 400-milligram once-daily raltegravir maintenance therapy
    Jintanat Ananworanich
    The HIV Netherlands Australia Thailand Research Collaboration HIV NAT, The Thai Red Cross AIDS Research Centre, Bangkok, Thailand
    Antimicrob Agents Chemother 56:1892-8. 2012
  9. doi Neither branded nor generic lopinavir/ritonavir produces adequate lopinavir concentrations at a reduced dose of 200/50 mg twice daily
    Reshmie A Ramautarsing
    The HIV Netherlands Australia Thailand Research Collaboration, Bangkok, Thailand
    J Acquir Immune Defic Syndr 59:55-8. 2012
  10. doi Pharmacokinetics and short-term efficacy of a double-boosted protease inhibitor regimen in treatment-naive HIV-1-infected adults
    Jasper van der Lugt
    HIV Netherlands Australia Thailand Research Collaboration, Thai Red Cross AIDS Research Center Bangkok, 104 Ratchadamri Road, Pathumwan, Bangkok 10330, Thailand
    J Antimicrob Chemother 61:1145-53. 2008

Collaborators

Detail Information

Publications19

  1. ncbi Pharmacokinetics and 48 week efficacy of adjusted dose indinavir/ritonavir in rifampicin-treated HIV/tuberculosis-coinfected patients: a pilot study
    Anchalee Avihingsanon
    HIV Netherlands Australia Thailand Research Collaboration, Thai Red Cross AIDS Research Center, Pathumwan, Bangkok, Thailand
    AIDS Res Hum Retroviruses 28:1170-6. 2012
    ..Despite good virological outcome in our cohort, prolonged exposure to subtherapeutic indinavir concentrations may lead to treatment failure...
  2. pmc Assessment of HBV flare in a randomized clinical trial in HIV/HBV coinfected subjects initiating HBV-active antiretroviral therapy in Thailand
    Anchalee Avihingsanon
    The Kirby Institute for Infection and Immunity in Society, University of New South Wales, Sydney, Australia
    AIDS Res Ther 9:6. 2012
    ..abstract:..
  3. doi Efficacy of tenofovir disoproxil fumarate/emtricitabine compared with emtricitabine alone in antiretroviral-naive HIV-HBV coinfection in Thailand
    Anchalee Avihingsanon
    HIV NAT, Thai Red Cross AIDS Research Centre, Bangkok, Thailand
    Antivir Ther 15:917-22. 2010
    ..However, there is limited randomized data on the efficacy of combined therapy with TDF and FTC, especially in antiretroviral (ARV)-naive patients...
  4. doi Plasma concentrations of generic lopinavir/ritonavir in HIV type-1-infected individuals
    Jasper van der Lugt
    The HIV Netherlands Australia Thailand Research Collaboration HIV NAT, Thai Red Cross Aids Research Centre TRCARC, Bangkok, Thailand
    Antivir Ther 14:1001-4. 2009
    ..However quality and safety remains an issue of concern. Therefore, we evaluated minimal plasma concentrations and short-term safety of a generic lopinavir/ritonavir 200/50 mg tablet formulation...
  5. doi Reducing the boosting dose of ritonavir does not affect saquinavir plasma concentrations in HIV-1-infected individuals
    Jasper van der Lugt
    The HIV Netherlands Australia Thailand Research Collaboration, Bangkok, Thailand
    AIDS 23:1176-9. 2009
    ..The 50% reduction of ritonavir boosting did not result in a change in the pharmacokinetics of saquinavir, whereas the ritonavir exposure was significantly lower when a dose of 50 mg was administered...
  6. doi Thai HIV-1-infected women do not require a dose increase of lopinavir/ritonavir during the third trimester of pregnancy
    Reshmie A Ramautarsing
    The HIV Netherlands Australia Thailand Research Collaboration, Bangkok, Thailand
    AIDS 25:1299-303. 2011
    ..To investigate whether Thai HIV-1-infected pregnant women require a dose increase of lopinavir/ritonavir (LPV/r) and to assess the safety and efficacy of the generic tablets during pregnancy...
  7. doi Pharmacokinetics and 48-week safety and efficacy of generic lopinavir/ritonavir in Thai HIV-infected patients
    Reshmie A Ramautarsing
    The HIV Netherlands Australia Thailand Research Collaboration HIV NAT, Bangkok, Thailand
    Antivir Ther 18:249-52. 2013
    ..We assessed pharmacokinetics, safety and efficacy of generic lopinavir/ritonavir (LPV/r) produced by the Government Pharmaceutical Organization (GPO) of Thailand in Thai HIV-infected adults...
  8. pmc Pharmacokinetics of and short-term virologic response to low-dose 400-milligram once-daily raltegravir maintenance therapy
    Jintanat Ananworanich
    The HIV Netherlands Australia Thailand Research Collaboration HIV NAT, The Thai Red Cross AIDS Research Centre, Bangkok, Thailand
    Antimicrob Agents Chemother 56:1892-8. 2012
    ..However, raltegravir at 400 mg QD was associated with a low C(trough) and with a risk for HIV viremia. Raltegravir at 200 or 300 mg BID should be studied, but new raltegravir formulations will be needed...
  9. doi Neither branded nor generic lopinavir/ritonavir produces adequate lopinavir concentrations at a reduced dose of 200/50 mg twice daily
    Reshmie A Ramautarsing
    The HIV Netherlands Australia Thailand Research Collaboration, Bangkok, Thailand
    J Acquir Immune Defic Syndr 59:55-8. 2012
    ..All patients remained virologically suppressed at week 12. In conclusion, LPV/r 200/50mg BID does not lead to adequate lopinavir plasma concentrations. Generic and branded LPV/r have comparable PK-parameters...
  10. doi Pharmacokinetics and short-term efficacy of a double-boosted protease inhibitor regimen in treatment-naive HIV-1-infected adults
    Jasper van der Lugt
    HIV Netherlands Australia Thailand Research Collaboration, Thai Red Cross AIDS Research Center Bangkok, 104 Ratchadamri Road, Pathumwan, Bangkok 10330, Thailand
    J Antimicrob Chemother 61:1145-53. 2008
    ..To study the pharmacokinetics and short-term efficacy of low and standard dose lopinavir/ritonavir and saquinavir combinations in Thai, human immunodeficiency virus (HIV)-infected, treatment-naive patients...
  11. ncbi Dyslipidemia in an Asian population after treatment for two years with protease inhibitor-containing regimens
    Stephen J Kerr
    The HIV Netherlands Australia Thailand Research Collaboration, Bangkok, Thailand
    J Int Assoc Physicians AIDS Care (Chic) 6:36-46. 2007
    ..Non-stavudine-containing non-boosted protease-inhibitor-based highly active antiretroviral treatment regimens had the least association with dyslipidemia...
  12. pmc Adherence and Risk Behaviour in Patients with HIV Infection Receiving Antiretroviral Therapy in Bangkok
    Amanda Clarke
    The HIV Netherlands Australia Thailand Research Collaboration HIV NAT, Thai Red Cross AIDS Research Centre, 104 Ratchadamri Road, Bangkok 10330, Thailand
    Open Virol J 6:23-8. 2012
    ..Nonetheless condom negotiation techniques, particularly in women, may be useful in this group...
  13. doi Impact of reverse transcriptase resistance on the efficacy of TMC125 (etravirine) with two nucleoside reverse transcriptase inhibitors in protease inhibitor-naïve, nonnucleoside reverse transcriptase inhibitor-experienced patients: study TMC125-C227
    K Ruxrungtham
    HIV NAT, Thai Red Cross AIDS Research Center and Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
    HIV Med 9:883-96. 2008
    ....
  14. doi Treatment of HIV infection with once-daily regimens
    Nitipong Permpalung
    Chulalongkorn University, Faculty of Medicine, Department of Medicine, Bangkok, Thailand
    Expert Opin Pharmacother 13:2301-17. 2012
    ..Treatment for HIV infection requires a lifetime antiretroviral therapy. In order to improve adherence, once daily (OD) is thus a preferred regimen...
  15. ncbi Pharmacokinetics and 48-week efficacy of nevirapine: 400 mg versus 600 mg per day in HIV-tuberculosis coinfection receiving rifampicin
    Anchalee Avihingsanon
    HIV NAT, Thai Red Cross AIDS Research Centre, Bangkok, Thailand
    Antivir Ther 13:529-36. 2008
    ..We aim here to determine the appropriate dose of nevirapine (NVP) in Thai HIV-tuberculosis (TB)-coinfected patients receiving rifampicin...
  16. doi Feasibility and efficacy of isoniazid prophylaxis for latent tuberculosis in HIV-infected clients patients in Thailand
    Mana Khongphatthanayothin
    Thai Red Cross AIDS Research Centre, Bangkok, Thailand
    AIDS Res Hum Retroviruses 28:270-5. 2012
    ..However, the long-term advantage of INH prophylaxis in terms of TB prevention, especially in HIV-1-infected patients on highly active antiretroviral therapy (HAART), is still an issue that needs more research...
  17. doi Impact of baseline virologic, immunologic, and demographic characteristics on virologic responses in the Gemini study
    Anchalee Avihingsanon
    HIV Netherlands Australia Thailand, Thai Red Cross AIDS Research Centre, Bangkok, Thailand
    HIV Clin Trials 13:111-7. 2012
    ..To determine the impact of baseline viral load (VL) and CD4+ cell count, race/ethnicity, and gender on response in a post hoc analysis of the Gemini study...
  18. doi Characterization of hepatitis B virus mutations in untreated patients co-infected with HIV and HBV based on complete genome sequencing
    Pisit Tangkijvanich
    Department of Biochemistry, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
    J Med Virol 85:16-25. 2013
    ..There was no major difference in the frequencies of common HBV mutations between co-infected and mono-infected patients. Thus, HBV mutations may not contribute to disease pathogenesis in Thai patients with co-infection...
  19. doi Active voluntary counseling and testing with integrated CD4 count service can enhance early HIV testing and early CD4 count measurement: experiences from the Thai Red Cross Anonymous Clinic in Bangkok, Thailand
    Nittaya Phanuphak
    The Thai Red Cross AIDS Research Centre, Bangkok, Thailand
    J Acquir Immune Defic Syndr 56:244-52. 2011
    ..Active voluntary counseling and testing (VCT) center with integrated CD4 count service may facilitate early HIV testing and CD4 count measurement...